Jazz Pharmaceuticals And PharmaMar Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period /// Jazz And PharmaMar Signed an Exclusive License Agreement on 19 December 2019 for Lurbinectedin in the United States - Jazz to Pay an Upfront Payment of $200 Million to PharmaMar /// PharmaMar is Also Eligible to Receive up to $800 Million in Potential Milestone Payments in Addition to Royalties on Net Sales .